Trial Profile
An Interaction Study to Assess the Effect of the Ezogabine/Retigabine and the Main Metabolite NAMR on the Pharmacokinetics of Digoxin in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Digoxin (Primary) ; Retigabine (Primary)
- Indications Conduction disorders; Epilepsy
- Focus Pharmacokinetics
- Sponsors GSK
- 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2012 New trial record